At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 77 enrolled
Drug / intervention
Dexamethasone +1 moredrug
Likely dose
Dexamethasone 0.1 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Dexamethasone as an Adjuvant to Ropivacaine for Femoral Nerve Blocks in Children Undergoing Knee Arthroscopy
In Brief
A Phase 3 clinical trial evaluating Dexamethasone and Ropivacaine for Knee Injury. Completed, enrolled 77 participants across 1 site.
Detailed Summary
If preservative-free dexamethasone 0.1 mg/kg (max dose 4 mg) is added to ropivacaine 0.5% 2 mg/kg (max dose 100 mg), then post-PACU opioid consumption will be reduced by 33%.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKnee Injury
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 2013
Enrollment StartJul 2014
Primary CompletionJul 2016
Study CompletionSep 2016
TodayJul 2026
First PostedOct 29, 2013
Enrollment StartJul 1, 2014
Primary CompletionJul 1, 2016
Study CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.7 years ago
Interventions
Dexamethasonedrug
Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
Ropivacainedrug
Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.